



NEWS RELEASE

Bio-Rad Reports First-Quarter 2025 Financial Results

2025-05-01

HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2025.

Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: "We navigated a highly dynamic first quarter that became progressively more challenging, yet we delivered solid margins through focused execution and careful expense management. Given the current levels of market uncertainty, we are moderating our full-year 2025 outlook to reflect the evolving macro environment. Going forward, we remain committed to advancing our growth and margin expansion initiatives."

Financial Results Highlights

GAAP Results		
	Q1 2025	Q1 2024
Revenue (millions)	\$ 585.4	\$ 610.8
Gross margin	52.3%	53.4%
Net income (millions)	\$ 64.0	\$ 383.9
Income per diluted share	\$ 2.29	\$ 13.45
Non-GAAP Results		
	Q1 2025	Q1 2024
Revenue (millions)	\$ 585.4	\$ 610.8
Gross margin	53.8%	54.2%
Net income (millions)	\$ 71.0	\$ 65.3
Income per diluted share	\$ 2.54	\$ 2.30

The non-GAAP financial measures shown in the table above and discussed below exclude certain items detailed later in this press release under the heading "Use of Non-GAAP and Currency-Neutral Reporting." A reconciliation between historical GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release.

First-Quarter 2025 Results

First-quarter 2025 total net sales were \$585.4 million, a decrease of 4.2 percent compared to \$610.8 million reported for the first quarter of 2024. On a currency-neutral basis, quarterly sales decreased 1.5 percent compared to the same period in 2024, primarily due to lower sales in our Life Science segment.

Life Science segment net sales for the first quarter were \$228.6 million, a decrease of 5.4 percent compared to the same period in 2024. On a currency-neutral basis, Life Science segment sales decreased by 3.5 percent compared to the same quarter in 2024. The currency-neutral year-over-year sales decrease was driven by ongoing challenges in the academic research market, particularly in the Americas.

Clinical Diagnostics segment net sales for the first quarter were \$356.8 million, a decrease of 3.2 percent compared to the same period in 2024. On a currency-neutral basis, net sales decreased 0.1 percent versus the same quarter last year. The currency-neutral year-over-year sales decrease was primarily driven by lowered reimbursements for diabetes testing in China, partially offset by increased demand for our quality control products.

First-quarter gross margin was 52.3 percent compared to 53.4 percent during the first quarter of 2024.

Income from operations during the first quarter of 2025 was \$23.7 million versus \$44.6 million during the same quarter last year.

During the first quarter of 2025, the company recognized a change in the fair market value of its investment in Sartorius AG, which substantially contributed to a net income of \$64.0 million, or \$2.29 per share, on a diluted basis, versus a net income of \$383.9 million, or \$13.45 per share, on a diluted basis, reported for the same period of 2024.

The effective tax rate for the first quarter of 2025 was 23.3 percent, compared to 21.8 percent for the same period in 2024. The higher rate in 2025 was driven by geographical mix of earnings.

Non-GAAP gross margin was 53.8 percent for the first quarter of 2025 compared to 54.2 percent during the first quarter of 2024.

Non-GAAP income from operations during the first quarter of 2025 was \$63.0 million versus \$59.0 million during the comparable prior-year period.

Non-GAAP net income for the first quarter of 2025 was \$71.0 million, or \$2.54 per share, on a diluted basis, compared to \$65.3 million, or \$2.30 per share, on a diluted basis, during the same period in 2024.

The non-GAAP effective tax rate for the first quarter of 2025 was 20.6 percent, compared to 22.4 percent for the same period in 2024. The lower rate in 2025 was driven by geographical mix of earnings.

Updated Full-Year 2025 Financial Outlook

Bio-Rad is updating its financial outlook for the full year 2025. The company currently expects non-GAAP, currency-neutral revenue to range from approximately a 1.0 percent decline to 1.5 percent growth versus its prior revenue growth estimate of approximately 1.5 to 3.5 percent, and an estimated non-GAAP operating margin of approximately 10.0 to 12.0 percent compared to its prior expectation of approximately 13.0 to 13.5 percent.

Conference Call and Webcast

Management will discuss the company's first quarter 2025 results and financial outlook in a conference call scheduled for 2:30 PM Pacific Time (5:30 PM Eastern Time) on May 1, 2025. To participate, dial (800) 715-9871 within the U.S., or (+1) (646) 307-1963 from outside the U.S., and provide access code: 9562470.

A live **webcast** of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at **investors.bio-rad.com**. A replay of the webcast will be available for up to a year.

Use of Non-GAAP and Currency-Neutral Reporting

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including non-GAAP net income and non-GAAP EPS, which exclude amortization of acquisition-related intangible assets, certain acquisition-related expenses and benefits, restructuring charges, asset impairment charges, gains and losses from change in fair market value of equity securities and loan receivable, gains and losses on equity-method investments, and significant legal-related charges or benefits and associated legal costs. Non-GAAP net income and non-GAAP EPS also exclude certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, tax provisions/benefits related to the previous items, and significant discrete tax events. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.

We utilize a number of different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of our business, in making operating decisions, forecasting and planning for future periods, and determining payments under compensation programs. We consider the use of the non-GAAP measures to be helpful in assessing the performance of the ongoing operation of our business. We believe that disclosing non-

GAAP financial measures provides useful supplemental data that, while not a substitute for financial measures prepared in accordance with GAAP, allows for greater transparency in the review of our financial and operational performance. We also believe that disclosing non-GAAP financial measures provides useful information to investors and others in understanding and evaluating our operating results and future prospects in the same manner as management and in comparing financial results across accounting periods and to those of peer companies. More specifically, management adjusts for the excluded items for the following reasons:

Amortization of purchased intangible assets: we do not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to purchased intangible assets and the term of amortization can vary significantly and are unique to each acquisition or purchase. We believe that excluding amortization of purchased intangible assets allows the users of our financial statements to better review and understand the historic and current results of our operations, and also facilitates comparisons to peer companies.

Acquisition-related expenses and benefits: we incur expenses or benefits with respect to certain items associated with our acquisitions, such as transaction costs, professional fees for assistance with the transaction; valuation or integration costs; changes in the fair value of contingent consideration, gain or loss on settlement of pre-existing relationships with the acquired entity; or adjustments to purchase price. We exclude such expenses or benefits as they are related to acquisitions and have no direct correlation to the operation of our on-going business.

Restructuring, impairment charges, and gains and losses from change in fair market value of equity securities and loan receivable, and gains and losses on equity-method investments: we incur restructuring and impairment charges on individual or groups of employed assets and charges and benefits arising from gains and losses from change in fair market value of equity securities and loan receivable, and gains and losses (including impairments) on equity-method investments, which arise from unforeseen circumstances and/or often occur outside of the ordinary course of our on-going business. Although these events are reflected in our GAAP financials, these unique transactions may limit the comparability of our on-going operations with prior and future periods.

Significant litigation charges or benefits and legal costs: we may incur charges or benefits as well as legal costs in connection with litigation and other contingencies unrelated to our core operations. We exclude these charges or benefits, when significant, as well as legal costs associated with significant legal matters, because we do not believe they are reflective of on-going business and operating results.

Income tax expense: we estimate the tax effect of the excluded items identified above to determine a non-GAAP annual effective tax rate applied to the pretax amount in order to calculate the non-GAAP provision for income taxes. We also adjust for items for which the nature and/or tax jurisdiction requires the application of a specific tax rate or treatment.

From time to time in the future, there may be other items excluded if we believe that doing so is consistent with the goal of providing useful information to investors and management.

Percentage sales growth in currency neutral amounts are calculated by translating prior period sales in each local currency using the current period's monthly average foreign exchange rates for that currency and comparing that to current period sales.

There are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact on our reported financial results. The presentation of this additional information is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP in the United States. Investors should review the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measures as provided in the tables accompanying this press release.

We do not provide a reconciliation of our non-GAAP financial expectations to expectations for the most comparable GAAP measure because the amount and timing of many future charges that impact these measures (such as amortization of future acquisition-related intangible assets, future acquisition-related expenses and benefits, future restructuring charges, future asset impairment charges, future valuation changes of equity-owned securities, future gains and losses on equity-method investments or future legal charges or benefits), which could be material, are variable, uncertain, or out of our control and therefore cannot be reasonably predicted without unreasonable effort, if at all.

BIO-RAD is a trademark of Bio-Rad Laboratories, Inc.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 7,500 employees, and \$2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com

Forward-Looking Statements

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding estimated future financial performance or results; remaining committed to advancing our growth and margin expansion initiatives; and for the full year 2025: currently expecting non-GAAP, currency-neutral revenue to range from approximately a 1.0 percent decline to a 1.5 percent growth versus its prior revenue growth estimate of approximately 1.5 to 3.5 percent, and an estimated non-GAAP operating margin of approximately 10.0 to 12.0 percent compared to its prior expectation of approximately 13.0 to 13.5 percent. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "expect," "estimate," "continue," "believe," "anticipate," "target," "will," "project," "assume," "plan," "remain," "may," "intend," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include risks relating to our international operations; global economic and geopolitical conditions; tariffs or other trade barriers; reductions in government funding or capital spending of our customers; the uncertain pace of the biopharma sector's recovery; international legal and regulatory risks; our ability to develop and market new or improved products; our ability to compete effectively; foreign currency exchange fluctuations; supply chain issues; product quality and liability issues; our ability to integrate acquired companies, products or technologies into our company successfully; changes in the healthcare industry; and natural disasters and other catastrophic events beyond our control. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's public reports filed with the Securities and Exchange Commission (the "SEC"), including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 to be filed with the SEC. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.

Bio-Rad Laboratories, Inc.
Condensed Consolidated Statements of Income
 (In millions, except number of shares, which are reflected in thousands, and per share data)
 (Unaudited)

	Three Months Ended March 31,	
	2025	2024
Net sales	\$ 585.4	\$ 610.8
Cost of goods sold	279.4	284.9
Gross profit	<hr/>	<hr/>
Selling, general and administrative expense	306.0	325.9
Research and development expense	208.8	214.9
Income from operations	73.5	66.4
Interest expense	<hr/>	<hr/>
Foreign currency exchange gains, net	23.7	44.6
	12.0	12.3
	(2.7)	(2.0)
	6	

Gains from change in fair market value of equity securities and loan receivable		(31.8)	(422.2)
Other income, net		(37.2)	(34.6)
Income before income taxes		83.4	491.1
Provision for income taxes		(19.4)	(107.2)
Net income	\$	64.0	\$ 383.9
Basic earnings per share:			
Net income per basic share	\$	2.29	\$ 13.46
Weighted average common shares - basic		27,941	28,518
Diluted earnings per share:			
Net income per diluted share	\$	2.29	\$ 13.45
Weighted average common shares - diluted		27,955	28,537

Bio-Rad Laboratories, Inc.
Condensed Consolidated Balance Sheets
(In millions)

	March 31, 2025	December 31, 2024
	(Unaudited)	
Current assets:		
Cash and cash equivalents	\$ 521.4	\$ 488.1
Short-term investments	1,139.0	1,176.4
Accounts receivable, net	424.7	452.5
Inventories, net	790.1	760.0
Other current assets	161.4	153.3
Total current assets	3,036.6	3,030.3
Property, plant and equipment, net	528.5	528.1
Operating lease right-of-use assets	153.2	160.5
Goodwill, net	414.6	410.5
Purchased intangibles, net	296.1	293.6
Other investments	4,994.2	4,839.2
Other assets	103.7	101.9
Total assets	\$ 9,526.9	\$ 9,364.1
Current liabilities:		
Accounts payable, accrued payroll and employee benefits	\$ 295.3	\$ 246.5
Current maturities of long-term debt	1.2	1.2
Income and other taxes payable	37.1	31.2
Other current liabilities	173.0	188.9
Total current liabilities	506.6	467.8
Long-term debt, net of current maturities	1,200.7	1,200.4
Other long-term liabilities	1,140.2	1,126.6
Total liabilities	2,847.5	2,794.8
Total stockholders' equity	6,679.4	6,569.3
Total liabilities and stockholders' equity	\$ 9,526.9	\$ 9,364.1

Bio-Rad Laboratories, Inc.
Condensed Consolidated Statements of Cash Flows
(In millions)
(Uncaudited)

	Three Months Ended March 31, 2025	2024
Cash flows from operating activities:		
Cash received from customers	\$ 640.0	\$ 638.3
Cash paid to suppliers and employees	(488.0)	(560.3)
Interest paid, net	(22.2)	(22.4)
Income tax payments, net	(7.9)	(3.8)
Other operating activities	8.0	18.0
Net cash provided by operating activities	129.9	69.8

Cash flows from investing activities:			
Payments for purchases of marketable securities and investments	(153.4)		(406.5)
Proceeds from sales and maturities of marketable securities and investments	190.7		403.6
Other investing activities	(34.4)		(40.2)
Net cash provided by (used in) investing activities	2.9		(43.1)
Cash flows from financing activities:			
Payments on long-term debt	(0.1)		(0.2)
Other financing activities	(97.6)		0.2
Net cash used in financing activities	(97.7)		-
Effect of foreign exchange rate changes on cash	(1.8)		2.7
Net increase in cash, cash equivalents and restricted cash	33.3		29.4
Cash, cash equivalents and restricted cash at beginning of period	489.8		404.4
Cash, cash equivalents and restricted cash at end of period	\$ 523.1	\$	433.8
Reconciliation of net income to net cash provided by operating activities:			
Net income	\$ 64.0	\$	383.9
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization	38.1		37.1
Reduction in the carrying amount of right-of-use assets	10.1		10.7
Gains from change in fair market value of equity securities and loan receivable	(31.8)		(422.2)
Changes in working capital	38.2		(40.7)
Other	11.3		101.0
Net cash provided by operating activities	\$ 129.9	\$	69.8

Bio-Rad Laboratories, Inc.
Reconciliation of GAAP financial measures to non-GAAP financial measures
(In millions, except number of shares, which are reflected in thousands, and per share data)
(Unaudited)

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including non-GAAP net income and non-GAAP diluted income per share (non-GAAP EPS), which exclude amortization of acquisition-related intangible assets; certain acquisition-related expenses and benefits; restructuring charges; asset impairment charges; gains and losses from change in fair market value of equity securities and loan receivable; gains and losses on equity-method investments; and significant legal-related charges or benefits and associated legal costs. Non-GAAP net income and non-GAAP EPS also exclude certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, tax provisions/benefits related to the previous items, and significant discrete tax events. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.

We utilize a number of different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of our business, in making operating decisions, forecasting and planning for future periods, and determining payments under compensation programs. We consider the use of the non-GAAP measures to be helpful in assessing the performance of the ongoing operation of our business. We believe that disclosing non-GAAP financial measures provides useful supplemental data that, while not a substitute for financial measures prepared in accordance with GAAP, allows for greater transparency in the review of our financial and operational performance. We also believe that disclosing non-GAAP financial measures provides useful information to investors and others in understanding and evaluating our operating results and future prospects in the same manner as management and in comparing financial results across accounting periods and to those of peer companies.

	Three Months Ended March 31, 2025		Three Months Ended March 31, 2024	
		% of revenue		% of revenue
GAAP cost of goods sold				
Amortization of purchased intangibles	\$ 279.4		\$ 284.9	
Restructuring benefits (costs)	(4.4)		(4.5)	
	(4.6)		(0.5)	
Non-GAAP cost of goods sold	<u>\$ 270.4</u>		<u>\$ 279.9</u>	
GAAP gross profit				
Amortization of purchased intangibles	\$ 306.0	52.3%	\$ 325.9	53.4%
Restructuring (benefits) costs	4.4		4.5	
	4.6		0.5	
Non-GAAP gross profit	<u>\$ 315.0</u>	53.8%	<u>\$ 330.9</u>	54.2%
GAAP selling, general and administrative expense				
Amortization of purchased intangibles	\$ 208.8		\$ 214.9	
Restructuring benefits (costs)	(0.6)		(1.1)	
	(15.3)		(4.4)	
Other non-recurring items (2)	(1.1)		(1.5)	
Non-GAAP selling, general and administrative expense	<u>\$ 191.8</u>		<u>\$ 207.9</u>	
GAAP research and development expense				
Acquisition related benefits (costs)	\$ 73.5		\$ 66.4	
Restructuring benefits (costs)	-		(0.2)	
	(13.3)		(2.2)	
Non-GAAP research and development expense	<u>\$ 60.2</u>		<u>\$ 64.0</u>	
GAAP income from operations				
Amortization of purchased intangibles	\$ 23.7	4.0%	\$ 44.6	7.3%
	5.0		5.6	

Acquisition related (benefits) costs	\$ -		\$ 0.2	
Restructuring (benefits) costs	\$ 33.2		\$ 7.1	
Other non-recurring items (2)	\$ 1.1		\$ 1.5	
Non-GAAP income from operations	\$ 63.0	10.8%	\$ 59.0	9.7%
GAAP (gains) losses from change in fair market value of equity securities and loan receivable	\$ (31.8)		\$ (422.2)	
Gains (losses) from change in fair market value of equity securities and loan receivable	\$ 31.8		\$ 422.2	
Non-GAAP (gains) losses from change in fair market value of equity securities and loan receivable	\$ -		\$ -	
GAAP other (income) expense, net	\$ (37.2)		\$ (34.6)	
Gains (losses) on equity-method investments	\$ 1.5		\$ (0.8)	
Non-GAAP other (income) expense, net	\$ (35.7)		\$ (35.4)	
GAAP income before income taxes	\$ 83.4		\$ 491.1	
Amortization of purchased intangibles	\$ 5.0		\$ 5.6	
Acquisition related (benefits) costs	\$ -		\$ 0.2	
Restructuring (benefits) costs	\$ 33.2		\$ 7.1	
(Gains) losses from change in fair market value of equity securities and loan receivable	\$ (31.8)		\$ (422.2)	
(Gains) losses on equity-method investments	\$ (1.5)		\$ 0.8	
Other non-recurring items (2)	\$ 1.1		\$ 1.5	
Non-GAAP income before income taxes	\$ 89.4		\$ 84.1	
GAAP provision for income taxes	\$ (19.4)		\$ (107.2)	
Income tax effect of non-GAAP adjustments (1)	\$ 1.0		\$ 88.4	
Non-GAAP provision for income taxes	\$ (18.4)		\$ (18.8)	
GAAP net income	\$ 64.0	10.9%	\$ 383.9	62.9%
Amortization of purchased intangibles	\$ 5.0		\$ 5.6	
Acquisition related (benefits) costs	\$ -		\$ 0.2	
Restructuring (benefits) costs	\$ 33.2		\$ 7.1	
(Gains) losses from change in fair market value of equity securities and loan receivable	\$ (31.8)		\$ (422.2)	
(Gains) losses on equity-method investments	\$ (1.5)		\$ 0.8	
Other non-recurring items (2)	\$ 1.1		\$ 1.5	
Income tax effect of non-GAAP adjustments (1)	\$ 1.0		\$ 88.4	
Non-GAAP net income	\$ 71.0	12.1%	\$ 65.3	10.7%
GAAP diluted income per share	\$ 2.29		\$ 13.45	
Amortization of purchased intangibles	\$ 0.18		\$ 0.20	
Acquisition related (benefits) costs	\$ -		\$ 0.01	
Restructuring (benefits) costs	\$ 1.19		\$ 0.25	
(Gains) losses from change in fair market value of equity securities and loan receivable	\$ (1.14)		\$ (14.79)	
(Gains) losses on equity-method investments	\$ (0.05)		\$ 0.03	
Other non-recurring items (2)	\$ 0.04		\$ 0.05	
Income tax effect of non-GAAP adjustments (1)	\$ 0.03		\$ 3.10	
Non-GAAP diluted income per share	\$ 2.54		\$ 2.30	
GAAP diluted weighted average shares used in per share calculation	27,955		28,537	
Shares included in non-GAAP net income per share, but excluded from GAAP net loss per share as they would have been anti-dilutive	\$ -		\$ -	
Non-GAAP diluted weighted average shares used in per share calculation	27,955		28,537	
Reconciliation of net income to adjusted EBITDA:				
GAAP net income	\$ 64.0	10.9%	\$ 383.9	62.9%
Interest expense	\$ 12.0		\$ 12.3	
Provision for income taxes	\$ 19.4		\$ 107.2	
Depreciation and amortization	\$ 38.1		\$ 37.1	
Foreign currency exchange gains, net	\$ (2.7)		\$ (2.0)	
Other income, net	\$ (37.2)		\$ (34.6)	
Gains from change in fair market value of equity securities and loan receivable	\$ (31.8)		\$ (422.2)	
Dividend from Sartorius AG	\$ 17.6		\$ 17.9	
Acquisition related (benefits) costs	\$ -		\$ 0.2	
Restructuring (benefits) costs	\$ 33.2		\$ 7.1	
Other non-recurring items (2)	\$ 1.1		\$ 1.5	
Adjusted EBITDA	\$ 113.7	19.4%	\$ 108.4	17.7%

- (1) Excluded items identified in the reconciliation schedule are tax effected by application of a non-GAAP effective tax rate. The non-GAAP tax provision is adjusted for items, the nature of which and/or tax jurisdiction requires the application of a specific tax rate or treatment.
- (2) Incremental costs to comply with the European Union's In Vitro Diagnostics Regulation ("IVDR") for previously approved products.

2025 Financial Outlook

Forecasted non-GAAP operating margin excludes 88 basis points related to amortization of purchased intangibles. Forecasted non-GAAP operating margin does not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance, such as foreign currency fluctuations, future gains or losses associated with certain legal matters, acquisitions and restructuring activities. We do not provide a reconciliation of our non-GAAP financial expectations to expectations for the most comparable GAAP measure because the amount and timing of many future charges that impact these measures (such as amortization of future acquisition-related intangible assets, future acquisition-related expenses and benefits, future restructuring charges, future asset impairment charges, future valuation changes of equity-owned securities, future gains and losses on equity-method investments or future legal charges or benefits), which could be material, are variable, uncertain, or out of our control and therefore cannot be reasonably predicted without unreasonable effort, if at all.

Investor Contact:

Edward Chung, Investor Relations
510-741-6104
ir@bio-rad.com

Media Contact:

Anna Gralinska, Corporate Communications
510-741-6643
cc@bio-rad.com

Source: Bio-Rad Laboratories, Inc.